Roivant Sciences
ROIV
70 hedge funds and large institutions have $1.47B invested in Roivant Sciences in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 22 increasing their positions, 4 reducing their positions, and 11 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 4
164% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 11
35% more funds holding
Funds holding: 52 → 70 (+18)
0.99% more ownership
Funds ownership: 50.45% → 51.44% (+0.99%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
15% less capital invested
Capital invested by funds: $1.72B → $1.47B (-$258M)
85% less call options, than puts
Call options by funds: $53K | Put options by funds: $355K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$10.4M |
| 2 |
BlackRock
New York
|
+$5.49M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.97M |
| 4 |
CC
Chicago Capital
Chicago,
Illinois
|
+$3.72M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$693K |
| 2 |
Squarepoint
New York
|
-$354K |
| 3 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$320K |
| 4 |
Two Sigma Investments
New York
|
-$248K |
| 5 |
Jane Street
New York
|
-$246K |
ROIV Hedge Fund Activity: Q2 2022 in Review
70 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q2 2022, worth a combined $1.47B — down 15% from $1.72B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ROIV positions and 11 closed out — a net gain of 18 holders — while 22 added to existing stakes and 4 trimmed.
The largest buyer was Two Seas Capital, adding an estimated $10.4M. The largest seller was Millennium Management, exiting entirely with an estimated $693K sold.
- 70 institutional investors held Roivant Sciences (ROIV) as of Q2 2022, up from 52 in Q1 2022.
- Funds reported $1.47B of Roivant Sciences stock for Q2 2022, down 15% quarter-over-quarter.
- 29 funds opened new Roivant Sciences positions in Q2 2022 and 11 closed out, a net change of +18 holders.
- The largest Roivant Sciences buyer in Q2 2022 was Two Seas Capital, an estimated $10.4M added.
- The largest Roivant Sciences seller in Q2 2022 was Millennium Management, an estimated $693K sold.
Based on aggregated 13F filings for Q2 2022.